Tag Archives: Arrowhead Pharmaceuticals

Medicare Price Negotiations; Lilly Targets HCPs Promoting Compounded GLP-1RAs; Arrowhead to Advance Obesity Pipeline; New AZ Ph2 Oral GLP-1RA Obesity Trial; Rivus Ph2 HFpEF Topline Results; Zealand and Fractyl Q2 ’24 Earnings Updates

A series of cardiometabolic-related news items have been observed from CMS, Lilly, Zealand, AstraZeneca, Fractyl Health, and Rivus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Ascletis MASH Development Updates; Biolinq Raises $58M for Intradermal Glucose Sensor; Arrowhead Initiates Ph3 Plozasiran Trials

Three cardiometabolic-related news items have been observed: Ascletis Pharma discontinues FDC MASH development in favor of other assets (view press release); Biolinq completed a $58M financing round to support the development of its intradermal glucose sensor (view press release); Arrowhead Pharmaceuticals initiated three new Ph3 trials for plozasiran: MUIR-3 (view CT.gov record) in HTG, and SHASTA-3 (view CT.gov record) and SHASTA-4 (view CT.gov record) in SHTG. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Arrowhead CY Q3 ’23 (FY Q4 ’23) Earnings; Zealand Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Two cardiometabolic-related news items have been observed: Arrowhead Pharmaceuticals hosted its CY Q3 ’23 (FY Q4 ’23) earnings call (view press release); and Zealand Pharma announced the appointment of Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here